A phase I study of a second-generation immunumodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies.

被引：0
|
作者：
Hwang, JJ
Martin, R
Fox-Sinclair, ES
Bahrani, A
Sullivan, T
Park, S
Agrawal, S
Burns, T
Waxdal, M
Marshall, JL
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[2] Hybridon Inc, Cambridge, MA USA
[3] FAST Syst Inc, Gaithersburg, MD USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6230S / 6230S
页数：1
相关论文
共 50 条
  • [31] Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.
    Papandreou, CN
    Pagliaro, L
    Millikan, R
    Daliani, D
    Herrmann, J
    Hong, Y
    Smith, M
    Adams, J
    Elliot, P
    Lightcap, E
    McCormack, T
    Pien, C
    Newman, R
    Logothetis, CJ
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 : 3730S - 3730S
  • [32] Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
    Park, Haeseong
    Garrido-Laguna, Ignacio
    Naing, Aung
    Fu, Siqing
    Falchook, Gerald Steven
    Piha-Paul, Sarina Anne
    Wheler, Jennifer J.
    Hong, David S.
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Kaseb, Ahmed Omar
    Oki, Yasuhiro
    Zinner, Ralph
    Patel, Shreyaskumar
    Bravo, Vivianne Marie Velez
    Fanale, Michelle A.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    Janku, Filip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] A phase I study of cloretazine® and temozolomide in patients with hematologic malignancies.
    Rizzieri, David A.
    Tse, William
    Khan, Khuda D.
    Advani, Anjali
    Donze, Jon
    Karsten, Verena
    Geller, Robert B.
    Gerson, Stanton L.
    [J]. BLOOD, 2006, 108 (11) : 557A - 558A
  • [34] Phase I study of continuous oral administration of lonafarnib (Sarasar™) in patients with advanced hematologic malignancies.
    List, AF
    DeAngelo, D
    O'Brien, S
    Cortes, J
    Wilson, J
    Sugrue, MM
    Zhu, YL
    Statkevich, P
    Baum, C
    Zaknoen, S
    [J]. BLOOD, 2002, 100 (11) : 789A - 789A
  • [35] A phase I study of the heparanase inhibitor PI-88 given subcutaneously (SQ) in patients (pts) with advanced solid malignancies.
    Basche, M
    Eckhardt, SG
    O'Bryant, CL
    Gore, L
    Witta, S
    Raj, S
    Schultz, MK
    Persky, M
    Morrow, M
    Grolnic, S
    Hunt, JE
    Creese, B
    Kangas, M
    Roberts, K
    Sawlwin, D
    Moore, J
    Holden, SN
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6140S - 6140S
  • [36] A phase I study of the selective apoptotic antineoplastic drug (SAAND) OSI-461 in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Holden, SN
    Basche, M
    Raj, SS
    Witta, S
    Gore, L
    Grolnic, S
    Brillhart, B
    Hunt, J
    Schultz, MK
    Morrow, M
    Gibbs, A
    Barrett, E
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6163S - 6163S
  • [37] Phase I trial of oral etoposide in combination with celecoxib in patients with advanced malignancies.
    Luu, TH
    Twardowski, P
    Leong, L
    Lim, D
    Morgan, R
    McNamara, M
    Portnow, J
    Ruel, C
    Shibata, S
    Synold, T
    Doroshow, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 241S - 241S
  • [38] Phase I/II trial with 111In-pentetreotide in patients with advanced malignancies.
    Argiris, A
    Peccerillo, K
    Murren, JR
    Cornelius, E
    Modlin, IM
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A515 - A515
  • [39] Phase I trial of oral cyclophosphamide in combination with celecoxib in patients with advanced malignancies.
    Twardowski, P
    Chow, W
    Koczywas, M
    Leong, L
    Lim, D
    Margolin, K
    Morgan, R
    Ruel, C
    Shibata, S
    Synold, T
    Doroshow, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 240S - 240S
  • [40] A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies.
    Oza, A
    Zamek, RM
    Siu, L
    Locsin, SM
    Moore, M
    Chen, F
    Chen, TL
    Cohen, P
    Rothermel, J
    Rubin, E
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 133 - 133
12345